Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership
You may also be interested in...
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.